Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBlue ocean capital advisors

    Blue Ocean Capital Advisors

    Jump to

    • Mkt consolidating, may see 3-5% upside/downside: Nipun Mehta

      Nipun Mehta, Founder & CEO, Blue Ocean Capital Advisors is of the view that market is currently consolidatng and it is possible for the Indian benchmark indices to see a 3-5 percent upmove or down move.

    • Upward momentum for mkt to continue; like autos, IT: Nipun Mehta

      Nipun Mehta, Founder & CEO, Blue Ocean Capital Advisors is of the belief that upward momentum for the market will continue, backed by strong foreign institutional investor (FII) buying.

    • What next if Fed hikes rates tomorrow?

      Nipun Mehta, Founder and CEO of Blue Ocean Capital Advisors says the Fed may hike rates from 15 basis points to 25 basis points as far as domestic markets are concerned.

    • Returns could take longer but buy on dips, says Nipun Mehta

      For investing, one should look at getting into fundamentally sound stocks and sectors that have consistently performed but the wait could be longer, says Nipun Mehta of Blue Ocean Capital Advisors.

    • Buy fundamentally sound cos, avoid midcaps: Experts

      According to Mehta, although the investment cycle is turning around decisively and green shoots are being seen across industries but there is no evident upswing yet.

    • Nippon Life hiking stake in Rel Cap: Should we invest now?

      P Phani Sekhar of Angel Broking and Nipun Mehta of Blue Ocean Capital Advisors believe it is the right time to buy the stock.

    • Avoid betting on Bank Nifty now; go for defensives: Sukhani

      In an interview to CNBC-TV18 market experts Sudarshan Sukhani of s2analytics.com, P Phani Sekhar of Angel Broking and Nipun Mehta of Blue Ocean Capital Advisors share their views on the market and specific stocks going ahead

    • Will you buy Ranbaxy amid uncertainty over 2 key generics?

      According to Mehta, of late Ranbaxy has been in the news for all the wrong reasons barring its merger with pharma behemoth Sun Pharma, making it a potential trigger for investors to buy the stock.

    • Nifty to see big bouts of resistance soon: Experts

      Rahul Mohindar of viratechindia.com advises investors to shy away from technology stocks and those from oil and gas space.

    • Sun Pharma a must in core portfolio: Experts

      Market experts Nipun Mehta and Dilip Bhatdo see no negatives for Sun Pharma if the Ranbaxy deal goes through.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347